FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2079084862> ?p ?o ?g. }

• W2079084862 endingPage "1958" @default.
• W2079084862 startingPage "1948" @default.
• W2079084862 abstract "We evaluated replication-defective poxvirus vectors (modified vaccinia Ankara [MVA] and fowlpox [FPV]) in a homologous and heterologous vector prime-boost vaccination regimen containing matching HIV inserts (MVA-HIV and FPV-HIV) given at months 0, 1, 3, 5 and 7 in 150 healthy HIV-negative vaccinia-naïve participants. FPV-HIV alone was poorly immunogenic, while the high dose (10 9 pfu/2 ml) of MVA-HIV alone elicited maximal responses after two injections: CD4+ and CD8+ T-cell responses in 26/55 (47.3%) and 5/60 (8.3%) of participants, respectively, and IFN-γ ELISpot responses in 28/62 (45.2%). The infrequent CD8+ T-cell responses following MVA-HIV priming were boosted only by the heterologous (FPV-HIV) construct in 14/27 (51.9%) of participants post 4th vaccination. Alternatively, HIV envelope-specific binding antibodies were demonstrated in approximately two-thirds of recipients of the homologous boosting regimen, but in less than 20% of subjects after the heterologous vector boost. Thus, a heterologous poxvirus vector prime-boost regimen can induce HIV-specific CD8+ T-cell and CD4+ T-cell responses, which may be an important feature of an optimal regimen for preventive HIV vaccination." @default.
• W2079084862 created "2016-06-24" @default.
• W2079084862 creator A5004036928 @default.
• W2079084862 creator A5010005336 @default.
• W2079084862 creator A5014680841 @default.
• W2079084862 creator A5014941587 @default.
• W2079084862 creator A5025852667 @default.
• W2079084862 creator A5026917180 @default.
• W2079084862 creator A5029359442 @default.
• W2079084862 creator A5029707643 @default.
• W2079084862 creator A5034536696 @default.
• W2079084862 creator A5049408338 @default.
• W2079084862 creator A5050612131 @default.
• W2079084862 creator A5053615892 @default.
• W2079084862 creator A5057987247 @default.
• W2079084862 creator A5058118396 @default.
• W2079084862 creator A5068920213 @default.
• W2079084862 creator A5075731113 @default.
• W2079084862 creator A5078714130 @default.
• W2079084862 creator A5084520588 @default.
• W2079084862 creator A5084682016 @default.
• W2079084862 creator A5089681670 @default.
• W2079084862 date "2011-02-24" @default.
• W2079084862 modified "2023-10-02" @default.
• W2079084862 title "A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects☆☆☆" @default.
• W2079084862 cites W1566106175 @default.
• W2079084862 cites W1655510925 @default.
• W2079084862 cites W1693158227 @default.
• W2079084862 cites W1966755343 @default.
• W2079084862 cites W1966980189 @default.
• W2079084862 cites W1982031759 @default.
• W2079084862 cites W1993846907 @default.
• W2079084862 cites W1995300440 @default.
• W2079084862 cites W2010391664 @default.
• W2079084862 cites W2013815517 @default.
• W2079084862 cites W2020100193 @default.
• W2079084862 cites W2020943564 @default.
• W2079084862 cites W2022990363 @default.
• W2079084862 cites W2030261331 @default.
• W2079084862 cites W2035803891 @default.
• W2079084862 cites W2038114373 @default.
• W2079084862 cites W2040258341 @default.
• W2079084862 cites W2048719253 @default.
• W2079084862 cites W2048999843 @default.
• W2079084862 cites W2056416333 @default.
• W2079084862 cites W2062690077 @default.
• W2079084862 cites W2064422480 @default.
• W2079084862 cites W2065411691 @default.
• W2079084862 cites W2070491512 @default.
• W2079084862 cites W2072191236 @default.
• W2079084862 cites W2075340091 @default.
• W2079084862 cites W2079176471 @default.
• W2079084862 cites W2083008217 @default.
• W2079084862 cites W2084808899 @default.
• W2079084862 cites W2088400322 @default.
• W2079084862 cites W2092721627 @default.
• W2079084862 cites W2096904495 @default.
• W2079084862 cites W2097771941 @default.
• W2079084862 cites W2103182811 @default.
• W2079084862 cites W2106628190 @default.
• W2079084862 cites W2129114331 @default.
• W2079084862 cites W2129304079 @default.
• W2079084862 cites W2149134545 @default.
• W2079084862 cites W2149860264 @default.
• W2079084862 cites W2152048324 @default.
• W2079084862 cites W2153670011 @default.
• W2079084862 cites W2155846302 @default.
• W2079084862 cites W2161134901 @default.
• W2079084862 cites W2162170852 @default.
• W2079084862 cites W2162342191 @default.
• W2079084862 cites W2162445884 @default.
• W2079084862 cites W2162803282 @default.
• W2079084862 cites W2162891851 @default.
• W2079084862 cites W2171987627 @default.
• W2079084862 cites W22129741 @default.
• W2079084862 cites W2998115530 @default.
• W2079084862 doi "https://doi.org/10.1016/j.vaccine.2010.12.104" @default.
• W2079084862 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3043112" @default.
• W2079084862 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21216311" @default.
• W2079084862 hasPublicationYear "2011" @default.
• W2079084862 type Work @default.
• W2079084862 sameAs 2079084862 @default.
• W2079084862 citedByCount "51" @default.
• W2079084862 countsByYear W20790848622012 @default.
• W2079084862 countsByYear W20790848622013 @default.
• W2079084862 countsByYear W20790848622014 @default.
• W2079084862 countsByYear W20790848622015 @default.
• W2079084862 countsByYear W20790848622016 @default.
• W2079084862 countsByYear W20790848622017 @default.
• W2079084862 countsByYear W20790848622018 @default.
• W2079084862 countsByYear W20790848622019 @default.
• W2079084862 countsByYear W20790848622021 @default.
• W2079084862 crossrefType "journal-article" @default.
• W2079084862 hasAuthorship W2079084862A5004036928 @default.
• W2079084862 hasAuthorship W2079084862A5010005336 @default.
• W2079084862 hasAuthorship W2079084862A5014680841 @default.
• W2079084862 hasAuthorship W2079084862A5014941587 @default.
• W2079084862 hasAuthorship W2079084862A5025852667 @default.

• next